Document 0229
 DOCN  M95B0229
 TI    In vitro inactivation of human immunodeficiency virus by ascorbic acid.
 DT    9511
 AU    Rawal BD; Bartolini F; Vyas GN; Department of Laboratory Medicine,
       University of California, San; Francisco 94143-0134, USA.
 SO    Biologicals. 1995 Mar;23(1):75-81. Unique Identifier : AIDSLINE
       MED/95344686
 AB    In vitro inactivation of cell-free human immunodeficiency virus (CFHIV)
       was investigated by mixing replication-competent virions with aliquots
       of a culture medium (RPMI) containing increasing amounts (62.5-500
       micrograms/ml) of ascorbic acid (AA) at pH7. Similarly, mixtures of
       CFHIV and 500 micrograms/ml AA in whole blood (WB) and leukocyte
       depleted blood (LDB) were made; control mixtures containing either CFHIV
       or AA alone in each experiment were included. After holding the mixtures
       for 3 h at 4 degrees C, the tubes containing WB and LDB mixtures were
       centrifuged to remove the blood cells. The respective supernatants,
       including the control aliquots, were layered over 0.5 x 10(6) MT2 cells
       in quadruplicate wells in microtitre plates. After 1 h of incubation at
       37 degrees C in an atmosphere of 5.0% carbon dioxide to permit contact
       of viable virions, the fluid in each well was replaced with RPMI
       containing 20% fetal bovine serum (FBS). The incubation was then
       continued at 37 degrees C for 5 days. On the basis of (1) absence of
       syncytia formation, (2) 100% viability of MT2 cells as compared with the
       cell controls, (3) absence of p24 antigen in the culture supernates, and
       (4) absence of HIV DNA in MT2 cells, we conclude that 500 micrograms/ml
       AA, in (a) RPMI, (b) WB, or (c) LDB, inactivated CFHIV in vitro.
       Furthermore, we determined that addition of 500 micrograms/ml AA to
       platelet concentrates did not adversely affect the platelet function
       tests during 5 days of storage at room temperature. These data warrant
       further work to evaluate the mechanism of CFHIV inactivation by
       treatment of blood products with AA.
 DE    Antiviral Agents/*PHARMACOLOGY  Ascorbic Acid/*PHARMACOLOGY  Blood
       Blood Platelets/DRUG EFFECTS  Cell Line  Cell-Free System  Culture Media
       Human  HIV/*DRUG EFFECTS  Support, U.S. Gov't, P.H.S.  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).